ArticleResearch square2025
Synergistic Angio-Osteogenic Effects of Copper-Releasing 3D Biocomposite Scaffolds: A Step Toward Vascularized Bone Regeneration.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Critical-sized bone defects present significant clinical challenges due to inadequate vascularization and scaffold integration. This study developed a multifunctional 3D-printed polycaprolactone (PCL)-gelatin (Gel) scaffold reinforced with Bioglass particles (BGPs) or copper dopped BGPs (CuBGPs) to synergistically enhance angiogenesis and bone regeneration in rat model. The scaffolds were fabricated by infiltrating gelatin solutions containing BGPs or CuBGPs into the pores of 3D-printed PCL matrices, followed by freeze-drying. Comprehensive characterization of PCL-gel, PCL-gel-BGPs, and PCL-gel-CuBGPs scaffolds revealed optimal porosity (58.76±5.20, 53.27±11.83, and 54.5±7.61%), contact angle (74.53 ±6.6, 71.76±2.65, and 69.89±4.14), and controlled degradation (44.65±4.73, 47.93±2.51, and 50.58±5.68). MTT study demonstrated dose-dependent enhancement of cell proliferation, with BGPs and CuBGPs significantly improving mesenchymal stem cells (MSCs) viability by day 5. In vivo experiments in rat calvarial defects showed that Cu containing scaffolds promoted greater new bone volume compared to other groups at 12 weeks. Histological and immunohistochemical analyses confirmed robust angiogenesis and woven bone formation, with CuBGPs achieving the highest vasculature. This study provides a detailed and reproducible framework for Cu-doped scaffold fabrication, characterization, and application in critical-sized defect regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.